Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Invivyd, Inc. (Nasdaq: IVVD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Invivyd is a Delaware-incorporated biopharmaceutical company whose common stock is listed on The Nasdaq Stock Market LLC under the symbol IVVD, as noted in multiple Form 8-K reports.
Through this page, readers can review Invivyd’s current and historical Form 8-K filings, which describe material events such as public offerings of common stock and pre-funded warrants, entry into underwriting agreements, clinical and regulatory milestones for its monoclonal antibody programs, and corporate governance changes. Examples include 8-Ks detailing underwritten offerings to fund commercial preparedness for VYD2311, research and development for RSV and measles programs, and formation of the SPEAR Study Group to study monoclonal antibody therapy for Long COVID and COVID-19 post-vaccination syndrome.
Invivyd’s filings also reference press releases on topics such as U.S. IND clearance and FDA alignment on the pivotal clinical program for VYD2311, Fast Track designation for VYD2311, selection of the RSV antibody candidate VBY329, and financial results for recent quarters. Other 8-Ks note Nasdaq correspondence regarding the company’s compliance with minimum bid price requirements and confirm that the matter was resolved after the company regained compliance.
On Stock Titan, Invivyd filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from each document. Users can quickly identify why a filing was made, what agreements or clinical developments it describes, and how it relates to Invivyd’s antibody pipeline, EUA-authorized PEMGARDA product, and capital-raising activities. This helps investors and researchers navigate lengthy regulatory documents and focus on the disclosures most relevant to IVVD’s business and stock.
Invivyd (IVVD)Exhibit 99.1
Invivyd, Inc. filed a current report to highlight a key regulatory milestone for its COVID-19 program. On October 6, 2025, the company issued a press release announcing U.S. IND clearance and alignment with the U.S. FDA on a pivotal clinical program for VYD2311, described as a vaccine-alternative antibody to prevent COVID. The press release was furnished as Exhibit 99.1 to this report.
Invivyd, Inc. filed a shelf registration on Form S-3 that describes its authorized monoclonal antibody PEMGARDA (pemivibart) for pre-exposure prophylaxis of COVID-19 in adults and adolescents 12 years and older weighing at least 40 kg who are moderately-to-severely immunocompromised and unlikely to mount an adequate vaccine response. The prospectus highlights the company’s investigational mAb VYD2311, which began dosing in a Phase 1/2 trial in September 2024 and showed positive full Phase 1/2 safety and pharmacokinetics data in June 2025. In August 2025 the company reported FDA advice supporting a compact Phase 2/3 trial that could support a BLA submission, subject to agreement on safety database size and protocol review. The filing reports ongoing variant neutralization updates in Jan 2025, Mar 2025, and Aug 2025, includes pro forma net tangible book value of approximately $169.1 million or $0.58 per share as of June 30, 2025, and notes pre-funded warrants exercisable for 21,342,442 shares and other offering mechanics.
Paul Bolno, a director of Invivyd, Inc. (IVVD), was granted a stock option on 09/22/2025 to buy 100,000 shares of common stock at an exercise price of $1.22 per share. The option expires on 09/21/2035. The grant vests over three years: one-third vests on the first anniversary of the grant and the remainder vests in equal monthly installments (1/36th) thereafter, subject to continuous service through each vesting date. Following the grant, the reporting person beneficially owns 100,000 option shares, held directly. The Form 4 was filed with a signature dated 09/24/2025 by an attorney-in-fact.
Invivyd Form 3 filed for Paul Bolno reports that Paul Bolno, identified as a director of Invivyd, Inc. (IVVD), has filed an initial Section 16 statement and discloses no securities beneficially owned as of the event date. The form lists the reporting person's address as c/o Invivyd, Inc., 209 Church Street, New Haven, CT. The filing is signed by an attorney-in-fact for Mr. Bolno and includes a Power of Attorney reference as an exhibit.
Invivyd, Inc. appointed Paul B. Bolno, M.D. to its Board of Directors and Compensation Committee, effective September 22, 2025, filling a vacancy created by the same-day resignation of director Christine Akinc, who left without any disagreement on company matters. Dr. Bolno will receive an annual cash retainer of $40,000 for Board service and $5,000 for Compensation Committee service.
He was also granted a nonqualified option to acquire 100,000 shares of common stock, vesting over three years from September 22, 2025, and exercisable for 10 years at the closing market price on the grant date under the 2021 Equity Incentive Plan. Separately, Nasdaq notified Invivyd on September 22, 2025 that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, and the matter is now closed.
Janus Henderson Group plc reported beneficial ownership of 24,271,759 shares of Invivyd, Inc. common stock, representing 11.6% of the class. The filing states Janus Henderson has shared voting and shared dispositive power over those 24,271,759 shares and no sole voting or dispositive power. The Schedule 13G identifies the reporting person as Janus Henderson Group plc (organized in Jersey) and lists indirect subsidiaries JHIUS, JHIUKL and JHIAIFML as registered investment advisers that furnished investment advice to Managed Portfolios. The statement includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is signed by Kristin Mariani, Head of North America Compliance, CCO, dated 09/08/2025.
RA Capital Management, Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund report collective beneficial ownership of 21,338,288 shares of Invivyd, Inc. (CUSIP 00534A102), representing approximately 9.99% of the outstanding common stock as of August 22, 2025. The Fund directly holds 17,119,096 shares plus pre-funded warrants exercisable for up to 21,342,442 shares, but the Pre-Funded Warrants include a Beneficial Ownership Blocker that prevents exercises that would raise ownership above 9.99%, limiting current exercisable holdings to 21,338,288 shares. RA Capital serves as investment adviser and has sole voting and dispositive power over the Funds holdings; Dr. Kolchinsky and Mr. Shah are identified as controlling persons and signed the filing on August 29, 2025.
Point72 group disclosed a passive 13G stake in Invivyd, Inc. The filing shows Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen beneficially own 16,730,467 shares, representing 8.0% of Invivyd's outstanding common stock based on 209,377,291 shares outstanding following the issuer's August 22, 2025 underwritten offering. The reported shares are held through Point72 Associates, LLC, with shared voting and dispositive power and no sole voting or dispositive power reported. The filing is submitted on a joint basis and states the position is not intended to influence control of the issuer.
Amendment No. 4 to a Schedule 13D reports that M28 Capital Management LP and Marc Elia hold common stock and director options in Invivyd, Inc. The filing states the reporting persons now beneficially own a combined 9,248,250 shares through shared voting and dispositive power attributed to M28 and an aggregate 9,548,250 shares when including Mr. Elia's 300,000 director stock options. Those amounts represent 4.4% (M28) and 4.6% (Elia) of the outstanding common stock, calculated using 209,377,291 shares outstanding per Invivyd's August 22, 2025 prospectus and press release. The amendment is an "exit filing" because, due solely to a change in the number of shares outstanding, the reporting persons no longer beneficially own more than 5% and are leaving the Schedule 13D reporting system. The director options were granted for board service; no transactions were effected in the past 60 days per the filing.